Robert J Kreitman
National Cancer Institute LAO · National Cancer Institute (NCI) · National Cancer Institute, National Institutes of Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert J Kreitman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06311227 · Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI) · active not recruiting · Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant · principal investigator
- Ph1NCT04815356 · Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and VariantNational Cancer Institute (NCI) · recruiting · Hairy Cell Leukemia, Hairy Cell Leukemia Variant · principal investigator
- N/ANCT04362865 · Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 InfectionNational Cancer Institute (NCI) · completed · COVID-19 · principal investigator
- Ph2NCT04324112 · Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCLNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia · principal investigator
- Ph2NCT04322383 · Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantNational Cancer Institute (NCI) · recruiting · Hairy Cell Leukemia · principal investigator
- Ph1NCT03805932 · Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia · principal investigator
- N/ANCT01087333 · Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentNational Cancer Institute (NCI) · recruiting · Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL) · principal investigator
- Ph2NCT01059786 · Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia · principal investigator
- Ph1/Ph2NCT00924170 · Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaNational Cancer Institute (NCI) · completed · Adult T-Cell Leukemia (ATL) · principal investigator
- Ph2NCT00924040 · Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell LeukemiaNational Cancer Institute (NCI) · terminated · Hairy Cell Leukemia · principal investigator
- Ph2NCT00923013 · Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia · principal investigator
- Ph2NCT00321555 · LMB-2 to Treat Hairy Cell LeukemiaNational Cancer Institute (NCI) · completed · Hairy Cell Leukemia · principal investigator
- Ph2NCT00080535 · Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell LymphomasNational Cancer Institute (NCI) · completed · Lymphoma, T-Cell, Cutaneous · principal investigator
- Ph2NCT00077922 · Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI) · completed · Leukemia, Lymphocytic, Chronic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Development of Recombinant Toxins to Treat Hematologic MalignanciesZIABC010301 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $3,020,282 awarded in 2025Same name and institution; not confirmed by an ID
- Patterns of immune response in COVID-19 patientsZIABC011952 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 to 2025 · $61,638 awarded in 2025Same name and institution; not confirmed by an ID
- Development of Recombinant Toxins to Treat Hematologic MalignanciesZ01BC010301 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 1998 to 2008 · $744,746 awarded in 2008Same name and institution; not confirmed by an ID
- Immunotoxin Therapy for Solid Tumors: Clinical studiesZ01SC006747 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 2000 to 2001Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:21 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.J Clin Oncol · 2018710 citationsRCR 25.4
- Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.N Engl J Med · 2001409 citationsRCR 8.8
- Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.Clin Cancer Res · 2007332 citationsRCR 7.4
- Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.J Clin Oncol · 2000331 citationsRCR 7.0
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Ann Oncol · 2022300 citationsRCR 22.1
- 299 citationsRCR 26.0
- Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.J Clin Oncol · 2012237 citationsRCR 6.3
- Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.J Clin Oncol · 2005217 citationsRCR 4.9
- Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.Clin Cancer Res · 2000210 citationsRCR 4.5
- Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.Sci Transl Med · 2013191 citationsRCR 5.3